Bausch + Lomb Corporation - BLCO STOCK NEWS

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced that five presentations concerning the XIPERE^® pivotal Phase 3 trial will be made at the American Society of Retina Specialists (ASRS) meeting from July 13-16, 2022, in New York. These presentations include a post-hoc analysis evaluating outcomes for macular edema linked to chronic uveitis. XIPERE^® is the first treatment approved in the U.S. for delivery through the suprachoroidal space, demonstrating clinical efficacy in improving visual acuity.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has expanded its Board of Directors by appointing Brett Icahn and Gary Hu from the Icahn Group, effective immediately. This follows an amended agreement that allows the Icahn Group to have two Board members post the distribution of 80% of Bausch + Lomb's shares from Bausch Health. CEO Joseph C. Papa expressed optimism about the appointments, indicating they will support efforts to unlock shareholder value and enhance the company's focus on integrated eye health solutions.

Bausch + Lomb Corporation has launched Revive™ custom soft contact lenses in the U.S., available in various options including spherical and multifocal designs. These lenses cater to patients with high prescriptions and unique vision needs, addressing previously challenging fits. They are made from non-ionic materials, allowing for daily wear for up to three months. Eye care professionals benefit from a 120-day EZ-Exchange™ program to ensure optimal patient fit. This launch exemplifies Bausch + Lomb's dedication to innovating eye care technologies.

Bausch + Lomb reported first-quarter 2022 revenues of $889 million, up 1% year-over-year, with organic revenue growth of 5%. The Vision Care and Surgical segments drove performance, while the Ophthalmic Pharmaceuticals segment saw a 5% decline. GAAP net income was $20 million, down from $27 million a year prior. Adjusted EBITDA was $170 million, a decrease of $28 million. The company forecasts full-year revenues of $3.75 to $3.80 billion, reflecting anticipated growth of 4-5%.

Bausch + Lomb announced seven presentations featuring research on their new Biotrue® Hydration Plus Multi-Purpose Solution and Biotrue® Hydration Boost lubricant eye drops at the American Optometric Association's Optometry's Meeting from June 7-8, 2022. The company aims to share clinical and antimicrobial efficacy data, particularly emphasizing the use of hyaluronan, a natural tear moisturizer. Additionally, Bausch + Lomb will host various sponsored education events during the meeting in Chicago from June 15-18, 2022, targeting eye care professionals and digital gamers.

Bausch + Lomb (NYSE/TSX: BLCO) has launched a social media campaign during June, recognized as Cataract Awareness Month, to enhance public knowledge about cataracts and the necessity of routine screenings. The initiative is driven by the pressing need to address cataracts, which affect over 25 million Americans and are projected to rise by 50% by 2032. Educators aim to alleviate patient anxiety regarding cataract surgery, a procedure noted for its safety and effectiveness. The campaign encourages open discussions between patients and eye care professionals under the hashtag #CataractsDontWait.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched its new Biotrue® Hydration Plus Multi-Purpose Solution in the U.S., designed for contact lens users. This solution features 25% more hyaluronan for increased moisture, effective cleaning, and a triple disinfectant system. Approximately one-third of the 45 million U.S. contact lens wearers suffer from dryness. The product is now available at major retailers with prices starting at $7.99. Bausch + Lomb also promotes recycling through its unique eye care recycling program.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) will announce its first-quarter 2022 financial results on June 8, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow to discuss the results and provide a business update. Materials will be available on the company's Investor Relations website before the call.

Founded in 1853, Bausch + Lomb focuses on eye health products, with a portfolio of over 400 products and a presence in nearly 100 countries.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has received approval from Health Canada for LUMIFY^®, the first over-the-counter eye drop containing low-dose brimonidine to relieve eye redness due to minor irritations. This innovative product will be available in Canada by July 2022. Clinical trials show LUMIFY^® significantly reduces ocular redness within one minute, lasting up to eight hours. It boasts a 95% satisfaction rating from a home-use study conducted with over 300 participants. This approval expands the company's portfolio in eye care products and addresses unmet needs in the market.